Researchers conducted a small, early-stage (Phase II) clinical trial to see if a combination of three drugs—durvalumab, doxorubicin, and ifosfamide—could help patients with a rare and hard-to-treat lung cancer called recurrent or metastatic pulmonary sarcomatoid carcinoma. The study included 20 patients who received the drug combination for up to four cycles, followed by one of the drugs alone for up to a year.
The main finding was that 7 out of the 20 patients (35%) experienced a measurable shrinkage of their tumors. For those who responded, the benefit lasted a median of about 5.3 months. The median time before the cancer started growing again was 4.8 months, and the median overall survival was 9.4 months. The study also reported that side effects were common, with serious adverse events occurring in half of the patients.
It is very important to interpret these results with caution. This was a small, single-arm study, meaning there was no comparison group to see if patients would have done just as well with a different treatment. The trial was also stopped early because of difficulty finding enough patients to enroll. While the results suggest this combination might have some activity against this rare cancer, they are not definitive. Larger, more robust studies are needed to confirm if this is a helpful treatment approach and to better understand its safety profile.
